Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistanceJulie Strizki, Nicholas Murgolo, Hiroshi Mohri et al.|Antimicrobial Agents and Chemotherapy|2023Cited by 33
153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitroJulie Strizki, Jay A. Grobler, Nicholas Murgolo et al.|Open Forum Infectious Diseases|2022Cited by 3